UNSPSC 51313211: Bamipine dihydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RG2UZ22FEZ, chemically known as 4-piperidinamine, 1-methyl-n-phenyl-n-(phenylmethyl)-, dihydrochloride, but more generally known as bamipine dihydrochloride, which bears US NIH Compound Identifier 109130. European Medicines Agency schedules bamipine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06098MIG.

Most nations, for tariff purposes, schedule bamipine dihydrochloride under HS 29333999. Bamipine dihydrochloride bears US NLM identifiers UMLS ID C0953071 and NCI Concept Code C103224. SMILES: CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.CL.CL.

UNSPSC 51313211 Bamipine dihydrochloride is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The recent opportunities tagged under this code reveal a significant mismatch: state and local governments are soliciting naloxone, safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products through cooperative purchasing vehicles and direct procurement mechanisms, but bamipine dihydrochloride—a vasodilator pharmaceutical with specific clinical applications—does not appear as a line item or focus in any of these solicitations. The code shows little relevant recent activity, suggesting either sparse demand for this specific pharmaceutical at the state and local level or inconsistent tagging of opportunities within procurement systems.

The three most-recent opportunities demonstrate broad-based state and local procurement interest in pharmaceuticals and allied products, but through channels and scopes unrelated to bamipine. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries to support community health. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026. These solicitations span Florida, Texas, and Minnesota-led cooperative purchasing serving multiple jurisdictions, but none target bamipine dihydrochloride as a procurement objective. Firms pursuing this code should verify actual demand signals with state health agencies and purchasing cooperatives before investing in response infrastructure.